Family · Pharmaceutical analytical standards
Lapatinib
An oral tyrosine kinase inhibitor that blocks two receptors at once, HER2 and EGFR; approved in the United States in 2007 and in Europe in 2008 for advanced HER2-positive breast cancer. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?While antibodies such as trastuzumab bind HER2 from outside the cell, lapatinib is a small molecule that enters the cell and switches the receptor off from the inside.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
